Hematologic malignancies: An opportunity to fill a gap in cancer surveillance

Cancer Causes and Control

Volumn 23, Issue 8, 2012, Pages 1253-1264

  Penberthy, Lynne ^a   Mcclish, Donna ^b   Peace, Steven ^c   Gray, Laurel ^d   Martin, Jim ^d   Overton, Sandra ^e   Radhakrishnan, Soundarya ^e   Gillam, Chris ^a   Ginde, Gordon ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d VIRGINIA DEPARTMENT OF HEALTH   (United States)

^e NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

Automation; Cancer reporting; Cancer surveillance; Claims data

Indexed keywords

ACCURACY; ARTICLE; AUTOMATED CANCER REPORTING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CHRONIC LYMPHATIC LEUKEMIA; COMMUNITY CARE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATICS; MYELOMA; NONHODGKIN LYMPHOMA; OUTPATIENT DEPARTMENT; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; VALIDATION PROCESS;

AMBULATORY CARE; DATA COLLECTION; EPIDEMIOLOGICAL MONITORING; HEMATOLOGIC NEOPLASMS; HOSPITALS; HUMANS; MEDICAL ONCOLOGY; MONITORING, AMBULATORY; NORTH CAROLINA; PILOT PROJECTS; REGISTRIES; VIRGINIA;

EID: 84864885127     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0003-1     Document Type: Article

References (47)

1. Decker SL, Schappert SM, Sisk JE (2009) Use of medical care for chronic conditions. Health Aff (Millwood) 28(1):26-35
2. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R (2006) Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 24(6):872-877
3. Cronin DP, Harlan LC, Clegg LX, Stevens JL, Yuan G, Davis TA (2005) Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol 23(2):73-81
4. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R (2003) Patterns of care for the treatment of bladder cancer. J Urol 169(5): 1697-1701
5. Warren JL, Harlan LC, Fahey A et al (2002) Utility of the SEER-medicare data to identify chemotherapy use. Med Care 40(8 Suppl):IV-55-IV-61
6. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R (2002) Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 20(7):1809-1817
7. Schenck AP, Klabunde CN, Warren JL et al (2008) Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service. Cancer Epidemiol Biomarkers Prev 17(4):799-804
8. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA (2004) Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev 13(1): 138-143
9. Penberthy LT, McClish D, Agovino P (2010) Impact of automated data collection from urology offices: improving incidence and treatment reporting in urologic cancers. J Registry Manag 37(4):141-147
10. Penson DF (2005) Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data? J Clin Oncol 23(31):7783-7784
11. Penberthy L, McClish D, Manning C, Retchin S, Smith T (2005) The added value of claims for cancer surveillance: results of varying case definitions. Med Care 43(7):705-712
12. Smith-Gagen J, Cress RD, Drake CM, Felter MC, Beaumont JJ (2005) Factors associated with time to availability for cases reported to population-based cancer registries. Cancer Causes Control 16(4):449-454
13. Seftel MD, Demers AA, Banerji V et al (2009) High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 33(11):1463-1468
14. Zent CS, Kyasa MJ, Evans R, Schichman SA (2001) Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 92(5):1325-1330
15. Cogle CR, Craig BM, Rollison DE, List AF (2011) Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117(26):7121-7125
16. Turesson I, Linet MS, Bjorkholm M et al (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121(10): 2260-2266
17. Skjelbakken T, Lochen ML, Dahl IM (2002) Haematological malignancies in a general population, based on information collected from a population study, hospital records, and the Cancer Registry of Norway: the Tromso Study. Eur J Haematol 69(2): 67-75
18. Astrom M, Bodin L, Tidefelt U (2001) Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population. Leuk Lymphoma 41(5-6):559-570
19. Maddocks KJ, Lin TS (2009) Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2:29
20. Kantarjian H, Schiffer C, Burnett A (2011) Hematologic malignancies: where do we stand in 2011? J Clin Oncol 29(5):473-474
21. Freedman A (2011) Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 86(9):768-775
22. Gribben JG (2010) How I treat CLL up front. Blood 115(2): 187-197
23. Redaelli A, Bell C, Casagrande J et al (2004) Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 4(1):85-96
24. Glaser SL, Clarke CA, Gomez SL, O'Malley CD, Purdie DM, West DW (2005) Cancer surveillance research: a vital subdiscipline of cancer epidemiology. Cancer Causes Control 16(9): 1009-1019
25. Wingo PA, Jamison PM, Hiatt RA et al (2003) Building the infrastructure for nationwide cancer surveillance and control-a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 14(2): 175-193
26. Albain KS, de la Garza SJ, Pienkowski T et al (2005) Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 6(5):412-420
27. Koh HK, Judge CM, Ferrer B, Gershman ST (2005) Using public health data systems to understand and eliminate cancer disparities. Cancer Causes Control 16(1):15-26
28. Hewitt M, Simone JV (2000) Enhancing data systems to improve the quality of cancer care. National Academies Press, Washington
29. North American Association of Central Cancer Registries (2011) Data Exchange Standards and Record Description Volume I-V. http://www.naaccr.org/ StandardsandRegistryOperations/VolumeI. aspx. Accessed 15 Nov 2001
30. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S (2007) Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 18(5): 561-569
31. National Cancer Institute (2011) Serveillance Epidemiology and End Results (SEER). http://seer.cancer.gov/siterecode-b/icdo3-d12192003. Accessed 15 Nov 2001
32. Gribben JG (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther 10(9): 1389-1394
33. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL (2004) The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 13(3):279-287
34. Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA (2008) Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 83(5):359-362
35. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Press, Fourth Edition
36. Johnson CH, Adamo M, Peace S, Percy-Laurry A (2012) 2010 Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual. National Cancer Institute. http://seer.cancer.gov/tools/heme/Hematopoitic-Instructions-and- Rules.pdf Accessed 19 April 2012
37. Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M (2007) Future supply and demand for oncologists : challenges to assuring access to oncology services. J Oncol Pract 3(2):79-86
38. American Cancer Society (2011) Chronic Lymphocytic Leukemia Overview. http://www.cancer.org/Cancer/Leukemia-Chronic LymphocyticCLL/OverviewGuide/ leukemia-cll-overview-keystatistics. Accessed 15 Nov 2011
39. Leukemia and Lymphoma Society (2011) Disease Information and Support: Hodgkin Lymphoma. http://www.lls.org/#/diseaseinformation/getinformationsupport/ factsstatistics/hodgkinlym phoma/. Accessed 15 Nov 2011
40. National Cancer Institute (2011) Leukemia. http://www.cancer. gov/cancertopics/types/leukemia. Accessed November 15, 2011
41. American Cancer Society (2011) Multiple Myeloma Overview. http://www.cancer.org/Cancer/MultipleMyeloma/OverviewGuide/multiple-myeloma- overview-key-statistics. Accessed 15 Nov 2011
42. Leukemia and Lymphoma Society (2011) Disease Information and Support: Non-Hodgkin Lymphoma http://www.lls.org/#/disease information/ getinformationsupport/factsstatistics/nonhodgkinlymphoma. Accessed 15 Nov 2011.a
43. Aisner J (2007) Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 64 (9 Suppl 5):S4-S7
44. Highlights of the NCCN 13th Annual Conference (2008) Oral Chemotherapy: here to stay, but questions remain. 5 Mar 2008
45. Michaud LB, Choi S (2008) Oral chemotherapy: a shifting paradigm affecting patient safety. The health care industry must make adjustments to accommodate this emerging chemotherapy modality. HemOncToday Issue November 25, 2008
46. The American Medical Association (2011) The differences between ICD-9 and ICD-10. Preparing for ICD-10 Code Set. Fact Sheet2. http://www.ama-assn.org/ ama1/pub/upload/mm/399/icd10-icd9-differences-fact-sheet.pdf. Accessed 15 Nov 2011
47. Williamson JM, Jones IH, Hocken DB (2011) How does the media profile of cancer compare with prevalencě Ann R Coll Surg Engl 93(1):9-12